Genomelink vs Doximity
Side-by-side comparison of AI visibility scores, market position, and capabilities
DNA app store enabling users to upload Ancestry/23andMe raw data for additional trait and health insights; $3.3M revenue positioned to capture 23andMe users after its 2024 bankruptcy filing.
About
Genomelink is a San Francisco-based DNA app store and personalized genomics platform that allows users to upload raw DNA data from Ancestry, 23andMe, or other consumer DNA tests and access a marketplace of analysis apps covering ancestry, traits, health predispositions, and wellness insights. Founded in 2017 and backed by $4.5-9 million from 500 Global, Asymmetry Ventures, and 27 total investors, Genomelink generated $3.3 million in revenue in 2024 with a 22-person team, serving consumers who want more from their raw genetic data than the original testing company provides.
Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.
About
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.